Zepbound for MASH and fatty liver: what the SYNERGY-NASH data really shows

Tirzepatide, the molecule in Zepbound and Mounjaro, resolved MASH in 44 to 62% of patients across dose arms in the SYNERGY-NASH phase 2 trial, the largest effect any drug has shown in the disease. Zepbound still has no FDA indication for MASH and no payer coverage under a MASH diagnosis. Wegovy does: the June 2026 semaglutide label added noncirrhotic MASH with stage F2 to F3 fibrosis in adults, under accelerated approval. With biopsy-confirmed MASH and obesity, you can still get Zepbound through the standard obesity prior-authorization route.

MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH) is the inflammatory stage of fatty liver disease; MASLD (formerly NAFLD) is the fat buildup before it. Both run on the same metabolic biology as obesity and type 2 diabetes.

What SYNERGY-NASH showed

SYNERGY-NASH randomized 190 patients with biopsy-confirmed MASH (stage F2 or F3 fibrosis) to tirzepatide 5, 10 or 15 mg weekly or placebo for 52 weeks, published in NEJM in June 2024.

• MASH resolution without fibrosis worsening: 44% on 5 mg, 56% on 10 mg, 62% on 15 mg, versus 10% placebo.
• Fibrosis improvement of one stage or more: 55% on 10 mg and 51% on 15 mg, versus 30% placebo. The 5 mg arm missed significance.
• Body weight down 10 to 16%, and liver fat on MRI-PDFF down 47 to 70%, across arms.

That roughly doubles resmetirom, the first FDA-approved MASH drug (March 2024), which hit 26% resolution in the MAESTRO-NASH 80 mg arm, though SYNERGY-NASH was phase 2 and smaller. Semaglutide has the phase 3 data: the ESSENCE trial of semaglutide 2.4 mg reported 63% resolution versus 34% placebo, with significant fibrosis improvement at 72 weeks, in late 2024. That is the trial behind the Wegovy MASH label. Tirzepatide has no reported phase 3 histology yet.

How to get it covered

The Wegovy MASH approval is accelerated, granted on MASH and fibrosis improvement, so Novo Nordisk still has to prove clinical benefit in a confirmatory trial. Nothing changed for Zepbound. Your routes:

• A MASH-coded PA, Wegovy only. MASH is in section 1 of the Wegovy label and nowhere on the Zepbound label, so a prior authorization can name the liver disease on one and not the other.
• The obesity route for Zepbound. MASH plus BMI 30, or BMI 27 with a comorbidity, qualifies under obesity, with MASH counting as the comorbidity. The PA cites obesity, not MASH.
• OSA or diabetes. With moderate-to-severe OSA the Zepbound OSA indication is a clean path, and about 35% of MASH patients have OSA. With type 2 diabetes, Mounjaro under the T2D indication is straightforward.

Eli Lilly could file a SYNERGY-NASH-based supplemental indication, but most analysts expect a phase 3 trial first, putting any Zepbound MASH label in 2027 to 2028. Some commercial plans are also expanding obesity coverage when MASH is documented, which is plan-by-plan and not consistent.

What you would pay and get

For biopsy-confirmed MASH and BMI 30 on Zepbound 15 mg at 52 weeks: roughly 55 to 65% MASH resolution, roughly 50% fibrosis improvement, and 15 to 20% weight loss. Cost with commercial insurance and an approved obesity PA runs $25 to $150 a month; cash-pay via LillyDirect vials is $299 to $449. Resmetirom, the FDA-approved alternative, is $1,300 a month before a savings card, typically $50 to $200 with commercial coverage. If your BMI is below 27 and the liver is the whole concern, the math changed in June 2026: the Wegovy MASH indication carries no BMI threshold, while off-label Zepbound cash-pay stays expensive without an insurance route.

Monitoring and who qualifies

Baseline liver labs, a FIB-4 or ELF score and an MRI-PDFF or FibroScan set your starting point, with non-invasive monitoring after; biopsy is increasingly de-emphasized as those markers improve. Most MASH patients carry company, which is why they qualify: about 60% have T2D or prediabetes, 75% a BMI of 30 or higher, 40% cardiovascular disease or major risk, 35% OSA, and 20% are on statins. Tirzepatide has heart-failure evidence from SUMMIT but no heart-failure indication, so HFpEF is not a coverage route.

Compounded, combinations and timing

Compounded tirzepatide is not a shortcut here. The FDA shortage that allowed broad 503A compounding ended in late 2024, so it is now available only under narrow medical-necessity carve-outs, off-label for an off-label use with added regulatory exposure. On timing, liver fat drops within 12 to 24 weeks, histologic resolution usually needs 52 weeks, and fibrosis improvement is slowest at 72 to 100 weeks. Resmetirom (a THR-beta agonist) plus tirzepatide (dual GLP-1 and GIP) is an emerging off-label combination for MASH plus obesity, but no completed RCT has tested it, so evidence is case-series only, and at $1,300 plus $299 to $449 a month before insurance most plans cover one and not both. Two FGF21 analogs, pegozafermin (reading out 2026 to 2027) and efruxifermin (phase 2b/3), could add by 2028, and tirzepatide's own phase 3 is expected to start in 2025 to 2026.

MASH plus obesity is a documentation game, and the right program wins it for you. Form Health writes detailed comorbidity PAs, Knownwell runs metabolic care with liver labs, and 9amHealth coordinates with specialty care. See Form Health's review for the full score.